KORU Medical appoints Adam Kalbermatten as chief commercial officer

MAHWAH, N.J. - KORU Medical Systems, Inc. (NASDAQ:KRMD), a medical device company with nearly 20% revenue growth over the past year and a market capitalization of $167 million, announced Monday the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025.

Kalbermatten brings over 20 years of commercial leadership experience in the medical device and pharmaceutical industries. In his new role, he will oversee KORU Medical’s global commercial strategy, including marketing, sales, market access, and pharmaceutical customer engagement. According to InvestingPro data, the company maintains a healthy gross profit margin of 63.5% and operates with moderate debt levels.

Prior to joining KORU Medical, Kalbermatten served as Vice President and General Manager of Advanced Drug Delivery Systems at Becton Dickinson (BD). He previously held the position of Chief Executive Officer at ZebraSci, where he led a turnaround strategy that culminated in the company’s acquisition by BD. His career also includes global leadership roles at Terumo Medical Corporation.

"Adam is a highly accomplished commercial leader with a strong presence in the market and deep customer relationships that have driven tangible business growth," said Linda Tharby, President and CEO of KORU Medical, in the company’s press release.

KORU Medical Systems develops and manufactures subcutaneous infusion solutions, including the FREEDOM Syringe Infusion System, which received its first FDA clearance in 1994. The company focuses on products for self-administration in home settings and use in ambulatory infusion centers.

The company’s stock trades on the Nasdaq under the ticker KRMD. The stock has shown strong momentum with a 43.7% return over the past year, and analysts have set price targets ranging from $3.50 to $7.00 per share. For deeper insights into KORU Medical’s valuation and growth prospects, including additional ProTips and comprehensive analysis, visit InvestingPro.

In other recent news, KORU Medical Systems reported a strong start to 2025 with Q1 revenue of $9.6 million, surpassing forecasts by 9.3% and marking an 18% year-over-year increase. This growth was driven by a 16% rise in domestic core revenue and a 36% increase in international core revenue. The company has raised its full-year revenue guidance to between $38.5 million and $39.5 million, reflecting anticipated growth of 15-17%. Additionally, KORU Medical Systems held its annual shareholder meeting, where all director nominees were successfully elected, and executive compensation received advisory approval. Cherry Bekaert LLP was ratified as the company’s independent registered public accountants for the fiscal year 2025. The company is also expanding its international presence and product pipeline, with strategic initiatives underway. Furthermore, KORU Medical Systems plans to submit two additional commercialized drugs for clearance by the end of 2025, adding to their pipeline of potential new opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.